Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 14/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.41 |
| ▸ | RELA | Q04206 | 2/20 | 0.41 |
| ▸ | MASP2 | O00187 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3147419 | 1.00 | F2 (0.51) | F2NFKB1PSMB5NFKB2RELA | |
| SCHEMBL3148675 | 0.86 | F2 (0.53) | F2NFKB1PSMB5NFKB2RELA | |
| SCHEMBL1432357 | 0.86 | F2 (0.53) | F2NFKB1PSMB5NFKB2RELA | |
| SCHEMBL1432535 | 0.86 | F2 (0.50) | F2MASP2 | |
| SCHEMBL1432531 | 0.86 | F2 (0.50) | F2MASP2 | |
| SCHEMBL3148648 | 0.85 | F2 (0.51) | F2MASP2 | |
| SCHEMBL1431737 | 0.85 | F2 (0.51) | F2MASP2 | |
| SCHEMBL1432594 | 0.84 | FURIN (0.45) | NFKB1PSMB5NFKB2RELAMASP2 | |
| SCHEMBL3149464 | 0.84 | FURIN (0.45) | NFKB1PSMB5NFKB2RELAMASP2 | |
| SCHEMBL1431802 | 0.84 | F2 (0.50) | F2MASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300428-A1 | AMINOPYRIDINE DERIVATIVES | Vantia Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | F2 1046/4885NFKB1 266/4885PSMB5 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.